Isis (ISIS) +9.2% after the FDA approved its Kynamro drug to treat HoFH, a rare genetic disorder...

|By:, SA News Editor

Isis (ISIS) +9.2% after the FDA approved its Kynamro drug to treat HoFH, a rare genetic disorder that causes extremely high cholesterol and heart attacks by the age of 30. While the drug is unlikely to be a blockbuster, it could be the first commercially viable medicine to use antisense technology, which can close down specific genes that cause disease and could have unlimited other uses. Partner Sanofi (SNY) is +1%, while it might also be worth watching antisense peer Sarepta (SRPT).